• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Elscint posts small gain for 1997

Article

Elscint's financial results for 1997 showed a slight profit as the Israeli company suffered from lower sales and tighter profit margins. Elscint was also affected by the devaluation of European currencies and its share of the net loss posted by its

Elscint's financial results for 1997 showed a slight profit as the Israeli company suffered from lower sales and tighter profit margins. Elscint was also affected by the devaluation of European currencies and its share of the net loss posted by its ELGEMS nuclear medicine joint venture with GE Medical Systems of Milwaukee.

For the year (end-December), Elscint recorded revenues of $303 million, down 3% compared with $311.4 million the year before. The Haifa company had a year-end profit of $709,000, compared with net income of $8.1 million the previous year. In the fourth quarter, Elscint had a net loss of $1 million on revenues of $80.4 million, compared with a net profit of $1.5 million on sales of $85.3 million in the fourth quarter of 1996.

Elscint cut expenses through 1997, and in the fourth quarter implemented a restructuring plan designed to cut additional costs and make the company more responsive to customers (SCAN 11/12/97). Elscint should begin to see the impact of that plan in 1998, although the effort adversely affected the company's fourth-quarter 1997 results, according to president and CEO Jonathan Adereth.

In other news, Elscint tapped a new CFO, naming Gaby Yankovitz to the position. Yankovitz replaces Yuval Yanai, who is leaving Elscint.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.